Story perspectives

Semaglutide: A Game-Changer for Heart Health, Not Just Weight Loss

10/25/2025

40 4

Summary

Story summary

The SELECT trial shows semaglutide (Wegovy) delivers significant cardiovascular benefits independent of weight loss.
Two-thirds of the reduction in major adverse cardiovascular events (MACE) was unrelated to weight changes.
The study shows a MACE risk decline with lower baseline weight and waist circumference, but no link to 20-week weight loss.
Experts say the findings could prompt guideline reevaluation and frame semaglutide as a disease-modifying therapy, not just a weight-loss agent.

1 of 1

Story summary

The SELECT trial shows semaglutide (Wegovy) delivers significant cardiovascular benefits independent of weight loss.
Two-thirds of the reduction in major adverse cardiovascular events (MACE) was unrelated to weight changes.
The study shows a MACE risk decline with lower baseline weight and waist circumference, but no link to 20-week weight loss.
Experts say the findings could prompt guideline reevaluation and frame semaglutide as a disease-modifying therapy, not just a weight-loss agent.